Skip to main content

July 2020, Vol 10, No 7

No improvement in survival or in any key secondary end point was observed when the checkpoint inhibitor atezolizumab (Tecentriq) was added to enzalu­tamide (Xtandi) for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the phase 3 IMbassador250 trial. The study results were presented at the 2020 American Association for Cancer Research virtual annual meeting.

Read Article ›

The addition of the checkpoint inhibitor atezolizumab (Tecentriq) to the 2 targeted therapies—the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib (Cotellic)—improved progression-free survival (PFS) and the duration of responses compared with the 2 targeted therapies plus placebo in patients with newly diagnosed advanced melanoma and BRAF V600E/K mutation, according to the phase 3 IMspire150 clinical trial. The results were presented at the 2020 American Association for Cancer Research virtual annual meeting by lead investigator Grant A. McArthur, MB BS (Hons), PhD, FRACP, FAHMS, Head, Cancer Therapeutics Program, Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.

Read Article ›

A Medically Integrated Pharmacy Care (MIPC) model represents the true integration of pharmaceutical and medical oncology care. At the virtual 2020 Community Oncology Alliance (COA) Community Oncology Conference, Jim Schwartz, RPh, Executive Director, Pharmacy Operations, Texas Oncology, Dallas, discussed this model, which he said provides clarity of focus around complex disease states.

Read Article ›

Breast cancer doctors got it right a long time ago when they began characterizing malignancies with classifications such as hormone-receptor and HER2 status, according to Alexander Spira, MD, PhD, FACP, Medical Oncologist, Virginia Cancer Specialists, Fairfax.

Read Article ›

For most patients with early-stage testicular germ cell tumors, surgery is curative and mitigates the risk for long-term toxicities associated with chemotherapy and radiation, according to results presented by Clint Cary, MD, MPH, Associate Professor, Department of Urology, Indiana University School of Medicine, Indianapolis, at the 2020 Genitourinary Cancers Symposium.

Read Article ›

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting.

Read Article ›

Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA.

Read Article ›

Most patients in the United States who receive stereotactic body radiation therapy (SBRT) for unfavorable intermediate- or high-risk localized prostate cancer are not receiving concurrent androgen-deprivation therapy (ADT), despite national guideline recommendations that support the concurrent use of ADT with radiation therapy.

Read Article ›

Combining the antibody drug conjugate, enfortumab vedotin (Padcev) with the immune checkpoint inhibitor pembrolizumab (Keytruda) showed encouraging results in patients with locally advanced or metastatic uro­thelial cancer who were unable to receive cisplatin-based chemotherapy in the first-line setting.

Read Article ›

Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma.

Read Article ›

Page 2 of 3